Controlled Release Personal Use Arthropod Repellent Formulation. Phase 2. Part 1.

Abstract : The overall objective of Phase II is to bring the prototype sustained release arthropod repellent formulation developed in Phase I to large scale manufacturing stage. This Phase II report details the work conducted during the past eight months for the development of a 12 hour sustained action arthropod repellent formulation. The work culminated in the development of BIOTEK sustained action Formulation 50I which meets virtually all the criteria and requirements of the contract; and the manufacture and submission to USAMRDC of 2,600 samples of the formulation in camouflaged and non-camouflaged labelled containers for evaluation. In addition an EPA Registration Package, a User Training Manual, and a Technical Data Package were prepared and submitted to the Army. Extensive evaluation of BIOTEK Formulation 50I was conducted: 1) in vitro on weanling pig skin 2) in vivo on human volunteers under controlled environments against a variety of mosquitoes; 3) in vivo on human volunteers in field test in Vero Bleach Florida against a variety of mosquitoes; 4) in rabbits against a variety of arthropods; 5) in rabbits to determine toxicity; and 6) for compatability with military materials. Troop Acceptability of the formulation was also determined on human volunteers of military age.